StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report released on Thursday. The firm issued a hold rating on the biotechnology company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback